These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 25609683)

  • 1. Trials and tribulations of noninferiority: caveat emptor.
    DiNubile MJ
    Clin Infect Dis; 2015 Apr; 60(8):1290-1. PubMed ID: 25609683
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply to DiNubile.
    Corey GR; Boucher HW; Stryjewski ME
    Clin Infect Dis; 2015 Apr; 60(8):1291-2. PubMed ID: 25609681
    [No Abstract]   [Full Text] [Related]  

  • 3. Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia.
    Stryjewski ME; Szczech LA; Benjamin DK; Inrig JK; Kanafani ZA; Engemann JJ; Chu VH; Joyce MJ; Reller LB; Corey GR; Fowler VG
    Clin Infect Dis; 2007 Jan; 44(2):190-6. PubMed ID: 17173215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Persistent bacteremia due to methicillin-resistant Staphylococcus aureus. A result of inadequate treatment].
    Parra-Ruiz J; Tomas-Jiménez C; Muñoz-Medina L; Hernández-Quero J
    Enferm Infecc Microbiol Clin; 2009 Jun; 27(6):372-3. PubMed ID: 19339080
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus.
    Charles PG; Ward PB; Johnson PD; Howden BP; Grayson ML
    Clin Infect Dis; 2004 Feb; 38(3):448-51. PubMed ID: 14727222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methicillin-Susceptible Staphylococcus Aureus Bacteremia: Cefazolin in Prime But Nafcillin Not Ready for an Exit.
    Sarria JC
    Am J Med Sci; 2020 Jul; 360(1):3-4. PubMed ID: 32439151
    [No Abstract]   [Full Text] [Related]  

  • 7. [Evaluation of pharmacodynamic target attainment with vancomycin treatment of bacteremia due to Staphylococcus aureus methicillin resistant].
    Lepe JA; Gil-Navarro MV; Santos-Rubio MD; Bautista J; Aznar J
    Rev Esp Quimioter; 2010 Mar; 23(1):43-7. PubMed ID: 20232023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Best alternative to vancomycin for serious methicillin-resistant Staphylococcus aureus infections: let's just say it.
    Bush LM
    Clin Infect Dis; 2011 Nov; 53(9):965-6. PubMed ID: 21880584
    [No Abstract]   [Full Text] [Related]  

  • 9. The empirical combination of vancomycin and a β-lactam for Staphylococcal bacteremia.
    McConeghy KW; Bleasdale SC; Rodvold KA
    Clin Infect Dis; 2013 Dec; 57(12):1760-5. PubMed ID: 23985343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group.
    Smith TL; Pearson ML; Wilcox KR; Cruz C; Lancaster MV; Robinson-Dunn B; Tenover FC; Zervos MJ; Band JD; White E; Jarvis WR
    N Engl J Med; 1999 Feb; 340(7):493-501. PubMed ID: 10021469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is high minimal inhibitory concentration of vancomycin a predictor of poor response in MRSA infections?
    Faulhaber G; Zavascki A; Fuchs SC
    Arch Intern Med; 2007 Jun; 167(11):1206-7; author reply 1208-9. PubMed ID: 17563032
    [No Abstract]   [Full Text] [Related]  

  • 12. [Use of glycopeptides in the treatment of infections caused by methicillin-resistant staphylococci].
    Bouza E; Rodríguez-Créixems M; Muñoz P
    Rev Clin Esp; 1997 Sep; 197 Suppl 2():52-8. PubMed ID: 9441324
    [No Abstract]   [Full Text] [Related]  

  • 13. Impact of initial antibiotic choice and delayed appropriate treatment on the outcome of Staphylococcus aureus bacteremia.
    Khatib R; Saeed S; Sharma M; Riederer K; Fakih MG; Johnson LB
    Eur J Clin Microbiol Infect Dis; 2006 Mar; 25(3):181-5. PubMed ID: 16505987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dalbavancin or oritavancin for skin infections.
    Corey GR; Jiang H; Moeck G
    N Engl J Med; 2014 Sep; 371(12):1162-3. PubMed ID: 25243251
    [No Abstract]   [Full Text] [Related]  

  • 15. Dalbavancin or oritavancin for skin infections.
    Baang J; Fisher S
    N Engl J Med; 2014 Sep; 371(12):1160-1. PubMed ID: 25229924
    [No Abstract]   [Full Text] [Related]  

  • 16. Dalbavancin or oritavancin for skin infections.
    Núñez-Núñez M; Rodríguez-Baño J
    N Engl J Med; 2014 Sep; 371(12):1160. PubMed ID: 25229923
    [No Abstract]   [Full Text] [Related]  

  • 17. Dalbavancin or oritavancin for skin infections.
    Boucher HW; Talbot GH; Dunne MW
    N Engl J Med; 2014 Sep; 371(12):1161-2. PubMed ID: 25229922
    [No Abstract]   [Full Text] [Related]  

  • 18. [MRSA infections in neonates and premature infants].
    Sunakawa K; Yokota T; Nitta Y
    Nihon Naika Gakkai Zasshi; 1992 Oct; 81(10):1646-51. PubMed ID: 1469316
    [No Abstract]   [Full Text] [Related]  

  • 19. Evaluation of vancomycin serum trough concentrations and outcomes in meticillin-resistant Staphylococcus aureus bacteraemia.
    Arshad S; Shoyinka A; Chen A; Jacobsen G; Zervos M
    Int J Antimicrob Agents; 2012 Nov; 40(5):474-5. PubMed ID: 22883416
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacology and the treatment of complicated skin and skin-structure infections.
    Chambers HF
    N Engl J Med; 2014 Jun; 370(23):2238-9. PubMed ID: 24897088
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.